Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04661514 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy
A Phase 2 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT04661514 is a Phase 2 study that has completed, run by University of California, San Diego. The registered enrollment target is 16 participants.
The verdict
NCT04661514, a Phase 2 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The primary aim of this study is to assess the safety and tolerability of one 25 mg dose of psilocybin in participants with anorexia nervosa based on adverse events (AEs), changes in vital signs, electrocardiograms (ECGs) and clinical laboratory tests. The secondary objectives are to explore the efficacy of a single 25 mg dose of psilocybin on eating disorder symptoms and behaviors, body image, anxiety, food related obsessions and rituals, and body weight.
Interventions
- DRUG Psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-05-01 |
| Est. Completion | 2022-06-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04661514
The ClinicalTrials.gov registry entry for NCT04661514 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Psilocybin is the first listed.
NCT04661514 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04661514 about?
NCT04661514 is a clinical study titled "Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy". The primary aim of this study is to assess the safety and tolerability of one 25 mg dose of psilocybin in participants with anorexia nervosa based on adverse events (AEs), changes in vital signs, electrocardiograms (ECGs) and clinical laboratory tests. The secondary objectives are to explore the eff...
What is the current status of trial NCT04661514?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2021-05-01. Estimated completion is 2022-06-10.
What interventions are being tested in trial NCT04661514?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT04661514?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.